WallStreetZenWallStreetZen

NASDAQ: NVAX
Novavax Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for NVAX

Based on 1 analyst offering 12 month price targets for Novavax Inc.
Min Forecast
$19.00+357.83%
Avg Forecast
$19.00+357.83%
Max Forecast
$19.00+357.83%

Should I buy or sell NVAX stock?

Based on 1 analyst offering ratings for Novavax Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NVAX stock forecasts and price targets.

NVAX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-01

1 of 1

Forecast return on equity

Is NVAX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is NVAX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

NVAX revenue forecast

What is NVAX's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$864.0M-12.17%
Avg 2 year Forecast
$1.0B+4.99%
Avg 3 year Forecast
$930.4M-5.42%
NVAX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NVAX revenue growth forecast

How is NVAX forecast to perform vs Biotechnology companies and vs the US market?
Company
0.03%
Industry
37.5%
Market
10.08%
NVAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NVAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NVAX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NVAX$4.15$19.00+357.83%Buy
NUVB$2.66$6.60+148.12%Strong Buy
LYEL$2.30$6.00+160.87%Buy
GHRS$11.08$39.50+256.50%Buy
SVRA$4.24$9.25+118.16%Strong Buy
View Top Biotech Stocks

Novavax Stock Forecast FAQ

Is Novavax Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NVAX) stock is to Buy NVAX stock.

Out of 1 analyst, 0 (0%) are recommending NVAX as a Strong Buy, 1 (100%) are recommending NVAX as a Buy, 0 (0%) are recommending NVAX as a Hold, 0 (0%) are recommending NVAX as a Sell, and 0 (0%) are recommending NVAX as a Strong Sell.

If you're new to stock investing, here's how to buy Novavax stock.

What is NVAX's revenue growth forecast for 2024-2026?

(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of 0.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Novavax's revenue in 2024 is $983,705,000.On average, 5 Wall Street analysts forecast NVAX's revenue for 2024 to be $120,913,077,707, with the lowest NVAX revenue forecast at $113,082,139,544, and the highest NVAX revenue forecast at $131,807,870,077. On average, 5 Wall Street analysts forecast NVAX's revenue for 2025 to be $144,547,804,685, with the lowest NVAX revenue forecast at $88,828,259,862, and the highest NVAX revenue forecast at $224,876,710,172.

In 2026, NVAX is forecast to generate $130,207,086,028 in revenue, with the lowest revenue forecast at $57,107,880,001 and the highest revenue forecast at $191,371,927,738.

What is NVAX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: NVAX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is NVAX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NVAX price target, the average NVAX price target is $19.00, with the highest NVAX stock price forecast at $19.00 and the lowest NVAX stock price forecast at $19.00.

The Wall Street analyst predicted that Novavax's share price could reach $19.00 by Mar 1, 2025. The average Novavax stock price prediction forecasts a potential upside of 357.83% from the current NVAX share price of $4.15.

What is NVAX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: NVAX) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.